版本:
中国

BRIEF-Bristol-Myers says discontinued development of drug to treat breast and gastric cancer in Q1

April 27 Bristol-Myers Squibb Co:

* Employee workforce reductions were about 900 for quarter-ended March 31, across all regions for manufacturing, selling, research and development personnel - SEC filing

* In Q1 2017, discontinued development of FS102 which was in Phase I development for treatment of breast and gastric cancer

* Will not exercise its option to purchase F-Star Alpha which was previously consolidated by company as a variable interest entity

* IPRD charge of $75 million was included in research and development expense and attributed to noncontrolling interest in Q1 Source text - (bit.ly/2oPSPvF) Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐